Wall Street analyst estimates for Pfizer Inc. (PFE): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis.
Consensus price target
$29.17 (-4 % vs price $30.52)
between $26.00 and $33.00 · 4 targets published in the last quarter
Closing price, Oct 30
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $62.2B | $61.3B – $63.0B | $2.95 | 13 |
| 2027E | $59.8B | $58.2B – $61.1B | $2.89 | 13 |
| 2028E | $54.7B | $50.9B – $57.6B | $2.48 | 7 |
Figures in USD · consensus as of October 29, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 15 |
| Hold | 23 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 39 |
| Avg rating (−2 sell to +2 buy) | 0.36 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-03 | $0.76 | ||
| 2026-08-04 | $0.77 | $0.68 | +12.9% |
| 2026-05-05 | $0.75 | $0.72 | +3.9% |
| 2026-02-03 | $0.66 | $0.57 | +16.4% |
| 2025-11-04 | $0.87 | $0.63 | +37.4% |
| 2025-08-05 | $0.78 | $0.58 | +34.5% |
| 2025-04-29 | $0.92 | $0.67 | +38.1% |
| 2025-02-04 | $0.63 | $0.47 | +33.6% |
Valuation Ratios
| P/E Ratio | 40.33 |
| Price / Book | 2.04 |
| EV / EBITDA | 17.51 |
| Dividend Yield | 5.64% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $52.82B | $52.55B | $40.83B | $40.91B | $41.65B | $81.29B | $101.17B | $59.55B | $63.63B | $62.58B |
| Cost of Revenue | $12.32B | $11.23B | $8.99B | $8.05B | $8.48B | $30.82B | $34.34B | $24.95B | $17.85B | $16.07B |
| Gross Profit | $40.50B | $41.32B | $31.84B | $32.85B | $33.17B | $50.47B | $66.83B | $34.60B | $45.78B | $46.51B |
| Research & Development | $7.89B | $7.68B | $7.76B | $8.38B | $9.39B | $13.83B | $11.43B | $10.68B | $10.82B | $10.44B |
| Selling, General & Admin | $14.84B | $14.80B | $12.61B | $12.73B | $11.60B | $12.70B | $13.68B | $14.77B | $14.73B | $13.79B |
| Operating Expenses | $26.79B | $27.25B | $25.11B | $25.54B | $24.34B | $30.23B | $28.71B | $30.18B | $30.84B | $29.11B |
| Operating Income | $13.71B | $14.07B | $6.73B | $7.31B | $8.83B | $20.23B | $38.12B | $4.42B | $14.94B | $17.41B |
| EBITDA | $15.29B | $19.84B | $11.06B | $18.65B | $13.26B | $30.79B | $41.03B | $9.56B | $18.13B | $16.78B |
| Interest Expense | $1.19B | $1.27B | $1.32B | $1.57B | $1.45B | $1.29B | $1.24B | $2.21B | $3.09B | $2.67B |
| Pre-tax Income | $8.35B | $12.30B | $3.59B | $11.32B | $7.04B | $24.31B | $34.73B | $1.06B | $8.02B | $7.52B |
| Income Tax | $1.12B | -$9.05B | -$266.0M | $583.0M | $370.0M | $1.85B | $3.33B | -$1.11B | -$28.0M | -$266.0M |
| Net Income | $7.21B | $21.31B | $11.15B | $16.03B | $9.16B | $21.98B | $31.37B | $2.12B | $8.03B | $7.77B |
| EPS | $1.18 | $3.57 | $1.90 | $2.92 | $1.65 | $3.95 | $5.59 | $0.38 | $1.42 | $1.36 |
| EPS (Diluted) | $1.17 | $3.52 | $1.87 | $2.87 | $1.63 | $3.88 | $5.47 | $0.37 | $1.41 | $1.36 |
| Shares Outstanding (Diluted) | 6,159.0 M | 6,058.0 M | 5,977.0 M | 5,675.0 M | 5,632.0 M | 5,708.0 M | 5,733.0 M | 5,709.0 M | 5,700.0 M | 5,686.0 M |
Price
| Price | $30.52 (closing price, October 30, 2026) |
| Market Cap | $174.0B |
| Exchange | NYSE |
| Country | US |
Related companies: MRK · GILD · SNY · LLY · JNJ · ABBV · AZN · NVS
Explore sector: Healthcare · Drug Manufacturers - General
More sections of PFE: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks